Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Long-Term Debt Issuances (2016 - 2025)

Historic Long-Term Debt Issuances for Guided Therapeutics (GTHP) over the last 13 years, with Q3 2025 value amounting to $108000.0.

  • Guided Therapeutics' Long-Term Debt Issuances fell 357.14% to $108000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $663000.0, marking a year-over-year increase of 11250.0%. This contributed to the annual value of $512000.0 for FY2024, which is N/A changed from last year.
  • Guided Therapeutics' Long-Term Debt Issuances amounted to $108000.0 in Q3 2025, which was down 357.14% from $150000.0 recorded in Q2 2025.
  • Guided Therapeutics' 5-year Long-Term Debt Issuances high stood at $1.4 million for Q3 2022, and its period low was -$1.4 million during Q4 2022.
  • Moreover, its 4-year median value for Long-Term Debt Issuances was $200000.0 (2024), whereas its average is $131000.0.
  • Its Long-Term Debt Issuances has fluctuated over the past 5 years, first surged by 58431.37% in 2022, then tumbled by 2500.0% in 2025.
  • Guided Therapeutics' Long-Term Debt Issuances (Quarter) stood at $204000.0 in 2021, then tumbled by 784.31% to -$1.4 million in 2022, then skyrocketed by 114.33% to $200000.0 in 2024, then crashed by 46.0% to $108000.0 in 2025.
  • Its last three reported values are $108000.0 in Q3 2025, $150000.0 for Q2 2025, and $205000.0 during Q1 2025.